Article Versions Notes

Tokunaga E, Masuda N, Yamamoto N, Iwata H, Bando H, Aruga T, Ohtani S, Fujisawa T, Takano T, Inoue K, et al. Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study). Cancers. 2021; 13(16):4008. https://doi.org/10.3390/cancers13164008

Tokunaga, Eriko, Norikazu Masuda, Naohito Yamamoto, Hiroji Iwata, Hiroko Bando, Tomoyuki Aruga, Shoichiro Ohtani, Tomomi Fujisawa, Toshimi Takano, Kenichi Inoue, and et al. 2021. "Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study)" Cancers 13, no. 16: 4008. https://doi.org/10.3390/cancers13164008

Tokunaga, E., Masuda, N., Yamamoto, N., Iwata, H., Bando, H., Aruga, T., Ohtani, S., Fujisawa, T., Takano, T., Inoue, K., Suganuma, N., Takada, M., Aogi, K., Sakurai, K., Shigematsu, H., Kuroi, K., Haga, H., Ohno, S., Morita, S., & Toi, M. (2021). Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study). Cancers, 13(16), 4008. https://doi.org/10.3390/cancers13164008